Start assessment ↗
Weight care Hormones & peptides Care team Pricing FAQ
Sign in Start assessment ↗

Pulsefield Weight Care · GLP-1 with muscle protection

LEANER.NOT WEAKER.

Lab-driven GLP-1 weight care that protects lean mass with a protein target, strength coaching and clinician-led dosing. A licensed clinician decides eligibility.

Start assessment ↗ See the protocol
Body weightSample client

−9.4%

Change across 12 weeks, with two dose step-ups

Lean mass held

94%

Week 12 scan, sample client

Protein streak

21days

Dose scheduleWeek 9 of 12
Now: Step 3 of 5Next: Step 4 at week 13, if tolerated

Sample client data for illustration. Individual results vary.

Why muscle matters on GLP-1

WEIGHT DROPS.
MUSCLE STAYS.

GLP-1 medications reduce appetite and food intake. Part of the weight lost can be lean tissue unless protein and resistance training are in place. The goal is to lose fat while keeping the muscle that drives strength, blood sugar control and daily energy.

  • A protein target set per kilogram of goal body weight
  • Three strength sessions a week, logged in the portal
  • Lean mass measured with a body-composition scan, not the scale alone
Body composition, sample trendIllustrative
Illustrative stacked bars of lean mass and fat mass in pounds at weeks 0, 4, 8 and 12 Total body weight falls from about 168 lb to about 141 lb. Lean mass stays near 90 to 93 lb. Fat mass falls from about 75 lb to about 50 lb. 168 lb 159 lb 148 lb 141 lb Week 0 Week 4 Week 8 Week 12

Illustrative. Example values to show the shape of the trend. Not patient data.

Medications

TWO MOLECULES.
CLEAR LABELS.

We prescribe semaglutide or tirzepatide when a licensed clinician decides you are a candidate. Each can come as a manufacturer brand or as a compounded version. Compounded medications are not FDA-approved.

Semaglutide

GLP-1 receptor agonist

Once-weekly injection

Weight-management brand
Wegovy
Same molecule, diabetes brand
Ozempic
Compounded version
Not FDA-approved. Made by a compounding pharmacy, not reviewed by the FDA for safety or effectiveness before sale.

Tirzepatide

GLP-1 and GIP receptor agonist

Once-weekly injection

Weight-management brand
Zepbound
Same molecule, diabetes brand
Mounjaro
Compounded version
Not FDA-approved. Made by a compounding pharmacy, not reviewed by the FDA for safety or effectiveness before sale.
Brand vs compounded, side by side
AttributeManufacturer brandCompounded
Who makes itThe drug manufacturer, under its own labelA compounding pharmacy, prepared to a prescription
FDA statusLabeled and reviewed by the FDA for its listed usesNot FDA-approved
Safety and potency reviewReviewed in clinical trials and printed on the labelNot reviewed by the FDA for safety or effectiveness before sale. Quality depends on the pharmacy.
Dose stepsPrinted titration schedule from the labelClinician sets the schedule. Confirm concentration with the pharmacy.

Semaglutide titration Example only

An example of how a labeled schedule steps up, shown for illustration. Your clinician sets your own schedule. Compounded medications are not FDA-approved, and their concentrations can differ.

  1. 0.25 mgWk 1–4
  2. 0.5 mgWk 5–8
  3. 1.0 mgWk 9–12
  4. 1.7 mgWk 13–16
  5. 2.4 mgWk 17+

Example only, not a prescription. Your clinician decides each increase based on tolerance.

Tirzepatide titration Example only

An example of how a labeled schedule steps up, shown for illustration. Your clinician sets your own schedule. Compounded medications are not FDA-approved, and their concentrations can differ.

  1. 2.5 mgWk 1–4
  2. 5 mgWk 5–8
  3. 7.5 mgWk 9–12
  4. 10 mgWk 13–16
  5. 12.5 mgWk 17–20
  6. 15 mgWk 21+

Example only, not a prescription. Your clinician decides each increase based on tolerance.

The protocol

FOUR RULES.
ONE PLAN.

Dose, protein, strength and check-ins run together. Each one is tracked, and the plan changes when your numbers do.

Dose

Your clinician starts low and steps the dose up gradually, only if side effects are manageable.

Set by: licensed clinician

Protein

A daily target of 1.2 g per kg of goal body weight, split across three or four meals and logged in the portal.

Set by: Marcus Hale RD, dietitian

Strength

Three sessions a week, 30 to 40 minutes, with progressive loads. Each session is logged against your week 1 baseline.

Tracked in: portal

Check-ins

Every two weeks during dose titration, then monthly. Each check reviews side effects, protein, strength and the dose step.

Led by: your clinical team

Twelve weeks

WEEK BY WEEK.

An example of the first 12 weeks in order. Each step builds on the one before it, and your clinician sets your own schedule.

  1. Week1

    Intake and baseline

    Clinician visit, medical history, baseline labs and a body-composition scan. Protein target set.

  2. Week2

    First dose

    Starting dose begins, the lowest step on the label. Injection technique reviewed in the first visit.

  3. Week3

    Strength begins

    Three sessions a week start. Loads are set from the baseline test and logged in the portal.

  4. Week4

    First check-in

    Side effects, hydration and appetite reviewed. First protein streak checked against the target.

  5. Week5

    First dose step

    Dose moves up only if tolerated. The clinician confirms before the change.

  6. Week6

    Meal plan tuned

    Dietitian reviews the protein log and adjusts meal timing where intake is short.

  7. Week7

    Load progression

    Strength loads increase where form holds. Missed sessions are re-planned, not doubled.

  8. Week8

    Second check-in

    Weight, waist and appetite trends reviewed together. Side effects and dose tolerance confirmed.

  9. Week9

    Dose step

    Next step on the ladder, if tolerated. Protein and strength logs reviewed the same week.

  10. Week10

    Hydration and labs

    Hydration and kidney function reviewed. Repeat labs ordered if your clinician indicates.

  11. Week11

    Strength re-test

    Repeat of the week 1 baseline lifts. The change is the number that matters, not the scale alone.

  12. Week12

    Scan, labs and next plan

    Week 12 body-composition scan and lab review. Your clinician sets the maintenance plan with you.

Side-effect support

WHEN THE STOMACH PUSHES BACK.

Nausea, constipation and low appetite are the most common early effects. Most ease with the adjustments below. Tell your clinic about anything that persists or worsens.

Nausea

Common in the first weeks and after each step up.

  • Smaller meals, eaten more slowly
  • Protein shakes or yogurt when whole meals feel heavy
  • Avoid lying down straight after eating

Constipation

Slower digestion is expected with GLP-1 medication.

  • Fiber from vegetables, legumes and whole grains
  • Steady fluid intake through the day
  • Daily walking, which also supports strength work

Low appetite and fatigue

Appetite drops, and protein can slip without a plan.

  • Protein target kept as the daily floor
  • Dietitian adjusts meal size and timing
  • Strength sessions shortened, not skipped, on low days

Dehydration

Vomiting or diarrhea can cause fluid loss quickly.

  • Sip fluids through the day, not all at once
  • Tell the clinic if you cannot keep fluids down
  • Hydration reviewed at every check-in

Call your clinic the same day if you have any of these

Vomiting that stops you keeping fluids down. Severe stomach pain that spreads to the back, which can signal pancreatitis. Yellowing of the skin or eyes. Symptoms of low blood sugar that do not settle. This list is not medical advice and does not replace urgent care. In an emergency, call emergency services.

Pricing

METABOLIC.
$279 A MONTH.

Care, coaching and monitoring in one monthly fee. Medication is billed separately, and the price is stated below so there are no surprises.

Metabolic

Muscle-first metabolic care

$279/mo

  • Clinician visits with Dr. Ava Lindqvist MD, sports and obesity medicine
  • Dietitian protein coaching with Marcus Hale RD
  • Strength program logged in the portal
  • Baseline and week 12 body-composition scan and lab review
  • Check-ins every two weeks during titration
Start assessment ↗

FAQ

FIVE QUESTIONS.

Important Safety Information

WARNING: RISK OF THYROID C-CELL TUMORS. In rodents, semaglutide and tirzepatide cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). It is unknown whether they cause thyroid C-cell tumors, including MTC, in people. Do not use if you or a family member has had MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tell your clinician about symptoms of thyroid tumors, such as a lump or swelling in the neck, hoarseness, trouble swallowing or shortness of breath.

Common side effects include nausea, diarrhea, vomiting, constipation, stomach pain and heartburn.

Serious side effects can include pancreatitis, gallbladder problems, low blood sugar (especially when used with insulin or a sulfonylurea) and kidney problems, including kidney failure, which can follow dehydration from vomiting or diarrhea.

Not for use in pregnancy. Tell your clinician right away if you may be pregnant or are planning a pregnancy.

Compounded medications are not FDA-approved. Eligibility is decided by a licensed clinician.

Results vary. Individual results vary, and the examples on this page are illustrative.

Read the full prescribing information

Each medication has a full prescribing information document from its manufacturer. Ask your clinician for it before you start, and read the boxed warning and the medication guide.

READY TOKEEP THE MUSCLE?

Start with the assessment. A licensed clinician reviews it, then decides whether a GLP-1 plan fits you.

Start assessment ↗

We use your email only to reply about this request.